Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Aesica Appoints Ian Muir to Commercial Managing Director Position

Published: Tuesday, February 04, 2014
Last Updated: Monday, February 03, 2014
Bookmark and Share
Key functions centre on the Group’s commercial business and product pipeline development across API, formulation development and formulated products.

Aesica has announced the appointment of Ian Muir to the newly created position of Commercial Managing Director, effective from 24th February. The position is reflective of the company’s plans for further global expansion and has international responsibility for all aspects of the commercial business.

The creation of the role reflects the strategic decision of Aesica to focus on its core commercial activities, with a global leadership structure primarily dedicated to the customer base. Ian Muir’s responsibilities cross all three of the company’s service offerings in API manufacture, formulation development and formulated products and he will lead the expansion of the business into new growth markets such as China and Japan.

Reporting directly to the CEO, Dr. Robert Hardy, Ian will be joining the Aesica Board. Under the new structure, Business Development, Sales and Marketing, Key Account and Product Management across Aesica will report directly to Ian who will be based at the company’s headquarters, in Newcastle, UK.

Ian holds a PhD in Pharmaceutical Science and with over 20 years’ experience in the pharmaceutical industry, his most recent role was at Catalent where he was responsible for the global provision of contract development and manufacturing services for oral dose forms.

He has significant commercial experience in contract manufacturing roles for large pharmaceutical companies located in Europe, the US and Australia and has been responsible for leading both R&D activities and commercial manufacturing operations. Furthermore, in previous roles, he grew a drug delivery business including in licensing key technologies from third parties in Japan and the rest of the world in controlled release tablet technology.

Dr. Robert Hardy, CEO said: “Ian brings strong commercial business knowledge and has proven experience of delivering growth and will play a pivotal role in driving further business growth for Aesica across API, formulation development and formulated products.”

Commenting on his new position, Ian said: “Aesica is fast growing, global CDMO with strong prospects for continued expansion supported by a solid client base and a full-service offering. I look forward to working with the company’s skilled personnel across all its sites to aid the company in achieving its vision to become the number 1 supplier of APIs and formulated products to the pharmaceutical industry.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Aesica Honoured with Prestigious Award
The CDMO secures the accolade for a sixth time through its talented personnel.
Monday, April 11, 2016
Aesica Adds Development Capability at Queenborough
Product life cycle services expanded including for high potent and controlled drugs.
Tuesday, April 05, 2016
The New Aesica Development Centre
Strategic relocation of development and clinical manufacturing services from Nottingham to Queenborough is now complete.
Wednesday, January 20, 2016
Aesica on Recruitment Drive at Queenborough Site
Aesica Pharmaceuticals has announced that it is actively recruiting for more skilled personnel at Queenborough ahead of the launch of its new development centre at the site.
Thursday, January 14, 2016
Bespak and Aesica Unveil New Single Source Supply Chain Solution
Supply chain solution for drug delivery device and pharmaceutical manufacturing services.
Friday, November 13, 2015
Aesica Introduces New Service Model with One CDMO
The company’s solution radically simplifies supply chain management – optimizing efficiency, improving performance and bringing products to market faster.
Wednesday, October 21, 2015
Aesica Launches New Brand Identity
Official launch to the market is planned for 13th October.
Tuesday, October 13, 2015
Aesica Secures Continuing FDA Approval of its Bulk Manufacture and Packaging Sites
FDA inspection results means Aesica will continue to grow its manufacturing and packaging services for pharmaceutical products for the US market.
Tuesday, February 03, 2015
Aesica Appoints VP, Business Development and Business Development Director
Appointment of Detlef Behrens and Sven Wrabletz for finished dose to drive service in Europe and achieve further growth.
Friday, October 31, 2014
Aesica Appoints New Product Release Manager
Company announces appointment of Adam Burgess.
Wednesday, August 20, 2014
Aesica Zwickau Marks 20th Anniversary
Continued growth and expansion of Company’s encapsulation services business.
Saturday, July 19, 2014
Aesica Recruits New Business Development Manager
Appointment of Nadine K. Reuter to aid sales drive across German, Austrian and Swiss Markets.
Thursday, July 03, 2014
Aesica Collaborates with QAD to Meet CFDA’s Shortened Serialization Deadline
The new system was implemented within three months.
Saturday, June 28, 2014
Aesica Successfully Introduces Serialization Services at Italian Site
Initiates commercial production of two product lines for the Chinese market.
Thursday, April 17, 2014
Aesica Led Consortium Wins Technology Strategy Board Grant
Funding secured for the consortium’s project to investigate an industrial biotechnology process to enable improved manufacture of an API.
Tuesday, April 08, 2014
Scientific News
Ketamine Metabolism Lifts Depression
NIH-funded team finds rapid-acting, non-addicting agent in mouse study.
Faster, Cheaper Way to Produce New Antibiotics
A novel way of synthesising a promising new antibiotic has been identified by scientists at the University of Bristol.
Process Contaminants in Vegetable Oils and Foods
Glycerol-based process contaminants found in palm oil, but also in other vegetable oils, margarines and some processed foods, raise potential health concerns for average consumers of these foods in all young age groups, and for high consumers in all age groups.
Known Genetic Risk Factors for Endometrial Cancer Doubles
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Improving Natural Killer Cancer Therapy
Vanderbilt University researchers discover transcription factor critical for NK cell expansion. Findings could lead to increased therapeutic efficacy.
Molecular Mechanism For Generating Specific Antibody Responses Discovered
Study could spur more ways to treat autoimmune disease, develop accurate vaccines.
Monovar Drills Down Into Cancer Genome
Rice, MD Anderson develop program to ID mutations in single cancer cells.
It’s Now Easier To Go With The Flow
Rice University tool simplifies comparison of flow cytometry data for laboratories.
Autism, Cancer Share a Remarkable Number of Risk Genes
Researchers with the UC Davis Comprehensive Cancer Center, MIND Institute identify more than 40 common genes.
Number Of Known Genetic Risk Factors For Endometrial Cancer Doubled
An international collaboration of researchers has identified five new gene regions that increase a woman’s risk of developing endometrial cancer, one of the most common cancers to affect women, taking the number of known gene regions associated with the disease to nine.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!